Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...
The latest edition of STAT’s Health Tech newsletter brings you important dispatches from the J.P. Morgan Health Care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback